NO992336L - Raf-kinase-inhibitorer - Google Patents

Raf-kinase-inhibitorer

Info

Publication number
NO992336L
NO992336L NO992336A NO992336A NO992336L NO 992336 L NO992336 L NO 992336L NO 992336 A NO992336 A NO 992336A NO 992336 A NO992336 A NO 992336A NO 992336 L NO992336 L NO 992336L
Authority
NO
Norway
Prior art keywords
methylphenyl
cyclohexylpropionylamino
acetoxybenzamide
hydroxybenzamide
raf kinase
Prior art date
Application number
NO992336A
Other languages
English (en)
Other versions
NO992336D0 (no
Inventor
Phillip John Hedge
Francis Thomas Boyle
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO992336L publication Critical patent/NO992336L/no
Publication of NO992336D0 publication Critical patent/NO992336D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Den foreliggende oppfinnelse vedrører farmasøytiske blandinger omfattende inhibitorer av raf-kinase med formel (l), hvori: R1 og R2 er substituenter på fenylringene; p, som kan ha de samme eller forskjellige verdier for R1 og R2, skal være 0-3, og når p er 2 eller 3, kan gruppene være de samme eller forskjellige; R3 er CMalkyl; q er 0-4; R4 er aryl eller cykloalkyl, hvori R4 eventuelt er substituert med opp til 3 subsituenter eller et farmasøytisk akseptabelt salt eller en in vivo hydrolyserbar ester derav og en farmasøytisk akseptabel bærer, under den forutsetning at N-[5-(3-cykloheksyl-propionylamino)-2-metylfenyl]-4-hydroksybenzamid, N-[5-(3-cyklopentylpropionylamino)-2-metylfenyl]-4-acetoksybenzamid, N-[5-(3-fenylpropionylamino)-2-metylfeny!]-4-acetoksybenzamid, N-[5-(4-cykloheksylbutyrylamino)-2-metylfenyl]-4-acetoksybenzamid, N-[5-(2-cykloheksylacetylamino)-2-metylfenyl]-acetoksybenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-aminobenzamid, Nt[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-nitrobenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-hydroksymetylbenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-metoksykarbonyl-benzamid, N-[5-(3-cykloheksylpropionylamino)2-metylfenyl]-2-hydroksybenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-3-hydroksybenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-benzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-acetoksybenzarnidog N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-hydroksybenzamider utelukket. Fremgangsmåter for deres fremstilling og deres anvendelse som terapeutiske midler. EEn spesiell anvendelse er i kreftterapi.
NO992336A 1996-11-16 1999-05-14 Raf-kinase-inhibitorer NO992336D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623833.2A GB9623833D0 (en) 1996-11-16 1996-11-16 Chemical compound
PCT/GB1997/003102 WO1998022103A1 (en) 1996-11-16 1997-11-12 Raf kinase inhibitors

Publications (2)

Publication Number Publication Date
NO992336L true NO992336L (no) 1999-05-14
NO992336D0 NO992336D0 (no) 1999-05-14

Family

ID=10803023

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992336A NO992336D0 (no) 1996-11-16 1999-05-14 Raf-kinase-inhibitorer

Country Status (8)

Country Link
EP (1) EP0941084A1 (no)
JP (1) JP2001504478A (no)
AU (1) AU4956297A (no)
CA (1) CA2267782A1 (no)
GB (1) GB9623833D0 (no)
NO (1) NO992336D0 (no)
WO (1) WO1998022103A1 (no)
ZA (1) ZA9710314B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
DK1017378T3 (da) 1997-09-23 2003-03-17 Astrazeneca Ab Amidderivater til behandling af sygdomme medieret af cytokiner
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
JP4437270B2 (ja) * 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
NZ505845A (en) * 1997-12-22 2003-10-31 Bayer Ag Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
IL139710A (en) 1998-05-15 2005-07-25 Astazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US6579872B1 (en) * 1998-05-15 2003-06-17 Astrazeneca Ab Bezamide derivatives for the treatment of diseases mediated by cytokines
BR9912729A (pt) 1998-08-04 2001-05-02 Astrazeneca Ab Derivado de amida, processo para prepará-lo, e, uso do mesmo
ATE254105T1 (de) 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
CN1158266C (zh) 1998-10-01 2004-07-21 阿斯特拉曾尼卡有限公司 化合物
US6194399B1 (en) 1998-10-09 2001-02-27 Scriptgen Pharmaceuticals, Inc. Aryldiamine derivatives useful as antibacterial agents
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1163212B1 (en) * 1999-03-17 2005-08-31 AstraZeneca AB Amide derivatives
DE60010448T2 (de) 1999-03-17 2005-04-07 Astrazeneca Ab Amid-derivate
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1456364B1 (en) 2001-12-21 2011-03-23 The Wellcome Trust Mutations in the b-raf gene
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
WO2004064733A2 (en) * 2003-01-15 2004-08-05 Board Of Regents, University Of Texas System The use of c-raf inhibitors for the treatment of neurodegenerative diseases
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
US7691870B2 (en) 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
WO2006007520A1 (en) * 2004-07-01 2006-01-19 Wisconsin Alumni Research Foundation Hydroxybenazamide compounds for treatment of cancer
AU2005278961A1 (en) * 2004-09-01 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as B-Raf inhibitors
AR053992A1 (es) * 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1957461B1 (en) * 2005-11-14 2016-11-02 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
WO2008140895A1 (en) 2007-04-20 2008-11-20 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20110281893A1 (en) * 2010-05-11 2011-11-17 Krisani Biosciences (P) Ltd Compound, synthesis, composition and uses thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2013032971A1 (en) 2011-08-29 2013-03-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
KR20140057629A (ko) 2011-08-29 2014-05-13 티코나 엘엘씨 방향족 아마이드 화합물
US9096794B2 (en) 2011-08-29 2015-08-04 Ticona Llc High flow liquid crystalline polymer composition
US8906258B2 (en) 2011-08-29 2014-12-09 Ticona Llc Heat-resistant liquid crystalline polymer composition having a low melting temperature
TW201319118A (zh) 2011-08-29 2013-05-16 Ticona Llc 低熔融黏度液晶聚合物之熔融聚合
US9045685B2 (en) 2011-08-29 2015-06-02 Ticona Llc Cast molded parts formed from a liquid crystalline polymer
CN103764793B (zh) 2011-08-29 2016-09-14 提克纳有限责任公司 高流动液晶聚合物组合物
WO2013032975A1 (en) 2011-08-29 2013-03-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004170A1 (en) * 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics

Also Published As

Publication number Publication date
JP2001504478A (ja) 2001-04-03
ZA9710314B (en) 1998-05-18
GB9623833D0 (en) 1997-01-08
CA2267782A1 (en) 1998-05-28
AU4956297A (en) 1998-06-10
WO1998022103A1 (en) 1998-05-28
EP0941084A1 (en) 1999-09-15
NO992336D0 (no) 1999-05-14

Similar Documents

Publication Publication Date Title
DE69921804D1 (de) Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten
DE69918404D1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
BG93979A (bg) Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им
EE03435B1 (et) Maatriksmetalloproteaasi inhibeeriva aktiivsusega ühendid, nende valmistamismeetodid ja kasutamine, vaheprodukt ja kompositsioon
RU95108243A (ru) Производные амидов вальпроновой и 2-вальпроеновой кислоты, фармацевтическая композиция, способы лечения
EE03139B1 (et) Piperasiiniderivaadid, nende kasutamine ja farmatseutiline kompositsioon
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
HUP0100558A2 (hu) S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben
ES8400393A1 (es) Un procedimiento para la preparacion de nuevos derivados de ariletanolamina.
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
UA49005C2 (uk) Похідні камптотецину (варіанти), спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
ATE153666T1 (de) Phosphono-arylethanolamin-verbindungen mit antihyperglykämischer und/oder antiobeser wirkung
ATE270550T1 (de) Wirkstoff zum schutz für organ oder gewebe
ES8606337A1 (es) Un procedimiento para preparar nuevas benzamidas con actividada antagonista de 5-ht.
HU895336D0 (en) Process for producing beta-delta-phenylthioxylosides and pharmaceutical compositions comprising such compounds as active ingredient
KR960706476A (ko) 인터류킨-1 활성 억제제로서의 신규한 벤젠설포닐아민 유도체(Novel benzen-esulfonylimine derivatives as inhibitors of lL-1 action)
DE69330601D1 (de) Serotoninergische ergolin derivate
BG88028A (bg) Амиди на циклометилен-1,2-дикарбоксилни киселини с терапевтична активност,методи за получаването им и фармацевтични състави, които ги съдържат
BG98238A (bg) Заместени бензотиазолови производни,получаванетоим и приложението им като хербициди
ES8300094A1 (es) "un procedimiento para preparar derivados de halofenil-piridil-alilamina".
RU95104890A (ru) Новые стероиды, содержащие в положении 20 аминозамещенную цепь, метод и промежуточные продукты подготовки данного метода, их применение в качестве медикаментов и включающие их фармацевтические соединения
FI935798A0 (fi) Alkylsubstituerade heterocykliska foereningar
DE69402004D1 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
DE69418110D1 (de) N-Heteroaryl substituierte Propanamid-Derivate brauchbar zur Behandlung cardiovascularer Krankheiten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application